136 related articles for article (PubMed ID: 31545288)
1. Investigating the regulation mechanism of baicalin on triple negative breast cancer's biological network by a systematic biological strategy.
Yang K; Zeng L; Ge A; Chen Z; Bao T; Long Z; Ge J; Huang L
Biomed Pharmacother; 2019 Oct; 118():109253. PubMed ID: 31545288
[TBL] [Abstract][Full Text] [Related]
2. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
Yang B; Huang J; Xiang T; Yin X; Luo X; Huang J; Luo F; Li H; Li H; Ren G
J Appl Toxicol; 2014 Jan; 34(1):105-12. PubMed ID: 24122885
[TBL] [Abstract][Full Text] [Related]
3. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
4. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
5. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
[TBL] [Abstract][Full Text] [Related]
6. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
[TBL] [Abstract][Full Text] [Related]
7. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
9. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
10. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
[TBL] [Abstract][Full Text] [Related]
11. Bisphenol A Increases the Migration and Invasion of Triple-Negative Breast Cancer Cells via Oestrogen-related Receptor Gamma.
Zhang XL; Liu N; Weng SF; Wang HS
Basic Clin Pharmacol Toxicol; 2016 Oct; 119(4):389-95. PubMed ID: 27038254
[TBL] [Abstract][Full Text] [Related]
12. Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway.
Hseu YC; Lin YC; Rajendran P; Thigarajan V; Mathew DC; Lin KY; Way TD; Liao JW; Yang HL
Food Chem Toxicol; 2019 Feb; 124():219-230. PubMed ID: 30529123
[TBL] [Abstract][Full Text] [Related]
13. Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway.
Wang XF; Zhou QM; Du J; Zhang H; Lu YY; Su SB
Anticancer Agents Med Chem; 2013 Jul; 13(6):923-31. PubMed ID: 23387975
[TBL] [Abstract][Full Text] [Related]
14. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
15. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.
Dey N; Young B; Abramovitz M; Bouzyk M; Barwick B; De P; Leyland-Jones B
PLoS One; 2013; 8(10):e77425. PubMed ID: 24143235
[TBL] [Abstract][Full Text] [Related]
16. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
17. The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential.
Chiang KC; Yeh TS; Chen SC; Pang JH; Yeh CN; Hsu JT; Chen LW; Kuo SF; Takano M; Kittaka A; Chen TC; Sun CC; Juang HH
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110769
[TBL] [Abstract][Full Text] [Related]
18. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
20. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
